Latest From CytoDyn Inc.
Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.
Pipeline Watch: Phase III Progress With Roche's Baloxavir, Pfizer's Tanezumab And Takeda's Vedolizumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
The company's monoclonal antibody for multidrug resistant HIV-1 patients licensed from TaiMed will launch soon.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- CytoDyn Inc.
- Senior Management
Nader Z Pourhassan, PhD, Pres. & CEO
Michael D Mulholland, CFO
Denis R Burger, PhD, CSO
- Contact Info
Phone: (360) 980-8524
1111 Main St., Ste. 660
Vancouver, WA 98660
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.